Boehringer Ingelheim registers Phase 3b trial of Survodutide in MASLD
This study was first posted on ClinicalTrials.gov on September 30, 2026. The trial plans to enroll 600 participants and planned start date is October 23, 2026.
Primary source
ClinicalTrials.gov registry record, September 30, 2026
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
Read the source: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation